南京诺唯赞生物科技股份有限公司2025年度业绩快报公告

Core Viewpoint - The company reported its preliminary financial results for the year 2025, indicating a stable revenue but a net loss, primarily influenced by changes in tax rates and performance-related adjustments [1][3]. Financial Performance Summary - The company achieved an operating revenue of 137,788.13 million yuan, remaining roughly the same as the previous year [1]. - The net profit attributable to the parent company was -1,697.02 million yuan, and the net profit after deducting non-recurring gains and losses was -7,936.03 million yuan, both showing a reduction in losses compared to the previous year [1]. - Total assets at the end of the reporting period were 491,959.27 million yuan, a decrease of 2.56% from the beginning of the period [2]. - The equity attributable to the parent company was 379,571.91 million yuan, down 3.79% from the beginning of the period [2]. Factors Affecting Performance - The increase in the value-added tax rate for biological products from 3% to 13% significantly impacted overall revenue and profitability [3]. - The company reversed previously accrued share-based payment expenses due to not meeting performance targets related to the 2023 restricted stock incentive plan [3]. - The company also reversed part of the previously recognized deferred tax assets, leading to an increase in income tax expenses [3]. - Other factors included increased sales expenses from expanding innovative and overseas markets, although research and management expenses saw a slight decrease after excluding the impact of share-based payment reversals [3]. Significant Changes - The company experienced a substantial reduction in operating profit and total profit compared to the previous year, primarily due to the cumulative effects of the factors mentioned above [4].